Juvenile myelomonocytic leukaemia (JMML) is a rare paediatric disease and allogeneic stem cell transplantation is the only curative approach. The roles of pretransplant treatment, conditioning regimen and graftversus-host disease (GVHD) are still unclear. Eleven children with JMML underwent allogeneic BMT in our institution. Donors were matched unrelated (n = 6) matched siblings (n = 4) and one mismatch family donor. Transplant-related mortality (TRM) was 36%. Three patients relapsed after transplantation. Two of three patients with relapse are in continuous remission after donor lymphocyte infusion or second BMT, respectively. To evaluate the role of pretransplant treatment, conditioning regimen and GVHD, we have summarised our series with other published single centre reports and give an overview on a total of 65 patients with JMML who underwent allogeneic BMT. No significant correlation between pretransplant treatment, conditioning regimen and TRM could be observed. Overall relapse rate is high (47%). TBI is associated with a significantly higher relapse rate (P = 0.012). Other conditioning modalities, intensive chemotherapy and splenectomy prior to stem cell transplantation do not seem to have a significant impact on relapse rate. Patients with or without GVHD showed no significant difference in relapse rate (58% vs 45%). In the event of relapse after transplantation withdrawal of immunosuppression, donor lymphocyte infusion or second transplant was successful in 6/11 patients. Graft-versusleukaemia effect seems to play an essential role in bone marrow transplantation for JMML. Bone Marrow Transplantation (2000) 26, 377-382.
tions, hepatosplenomegaly, lymph node enlargement and cutaneous xanthogranuloma or typical facial rash. 1, 2 Haematological findings are characterised by thrombocytopenia, leukocytosis with an increase of mature and immature myeloid cells and monocytes in the absence of the Philadelphia chromosome. Approximately 25% of patients have monosomy 7 and 10% other chromosomal aberrations. In patients without monosomy 7, elevated HbF levels can frequently be detected. 2, 3 Children with neurofibromatosis type 1 are at increased risk of developing JMML. 3, 4 Despite different treatment protocols, such as cytokines, single agent chemotherapy or intensive combination chemotherapy, the probability of 10 year survival without allogeneic bone marrow transplantation (BMT) is very poor (6%). 2, 5 Only in a small subgroup of patients with different favourable prognostic factors (ie young age, platelet count Ͼ100 × 10 9 /l, normal HbF level) has a longterm benefit of intensive chemotherapy been observed. 6, 7 On the other hand, BMT is associated with high transplant-related mortality (TRM), especially in children receiving BMT from unrelated donors and the relapse rate is high. Arnold et al 8 for the EBMT Chronic Leukaemia Working Party report a TRM of 18% in 12 patients transplanted for JMML from unrelated donors. Data published by Locatelli et al 9 for the European Working Group on Myelodysplastic Syndromes in Childhood reveal a TRM of 46% after transplants from alternative donors vs 9% after matched sibling transplants.
This report presents the data and the disease course of 11 children who underwent BMT for JMML, and reviews and summarises the single centre experiences published to date.
Patients and methods
Eleven children with JMML underwent allogeneic BMT between 1990 and 1998 in the St Anna Children's Hospital. Three of these patients have been published previously in the EWOG report 1997. 9 Patient data at diagnosis and pretransplant treatment are listed in Table 1 . Median age at diagnosis was 1.6 years (range 0.3-11.4). Cytogenetic bone marrow examination revealed monosomy 7 in three patients and other chromosomal abnormalities in two; Philadelphia chromosome was absent in all cases. None of the patients had neurofibromatosis type 1. At diagnosis the median leukocyte count in peripheral blood was 41 g/l (range 7.1-262), the median platelet count 60 g/l (range , the median monocyte count was 3250/l (range 219-34 000) and the median blast count was 644/l (range 170-21 000). Foetal haemoglobin level was assessed in 10 patients, and elevated levels were detected in 7/8 patients without monosomy 7 with a median level of 25% (range 15-90%). Eight children had received Ara-C and etoposidecontaining chemotherapy regimens before BMT, and three had received mercaptopurine maintenance therapy only. Remission could not be induced in any of the children before BMT.
Median age at BMT was 2.7 years (range 0.8-11.7). Median interval between diagnosis and BMT was 6.6 months (range 3.7-30.9). Absolute leukocyte counts before BMT ranged between 0.7 and 42.8 g/l (median 18 g/l), and organomegally was still present in all patients at the time of BMT. Two patients underwent splenectomy before transplantation and six patients had splenic irradiation to 5 Gy.
Viral infections (HHV6, CMV, parvovirus and adenovirus) were detectable by PCR in six patients before transplantation.
Conditioning regimens, donor, cell dose and graftversus-host disease (GVHD) prophylaxis are listed in Table 2 .
Donors were HLA-matched unrelated in six cases, matched siblings in four, and 1AG mismatched mother in one case. All patients received non-T cell-depleted bone marrow. The infused cell number ranged from 1.7 to 16.2 × 10 6
CD34
+ cells per kg body weight of the recipient, and from 4 to 37 × 10 7 CD3 + cells. GVHD prophylaxis consisted of cyclosporin with shortcourse MTX (n = 8), and in MTX only for patients less than 10 years old with HLA-identical sibling donors (n = 3). Acute and chronic GVHD were graded according to the consensus criteria. 10 Engraftment was monitored by FISH analysis of the sex chromosome in the case of sexmismatched transplantations, and by VNTR or STR-PCR in whole PB and BM samples as well as in specific subsets isolated by flow sorting. 11 The following data were analysed for evaluation of previously published single centre experiences: clinical and laboratory findings at diagnosis, pretransplant treatment, interval between diagnosis and BMT, conditioning regimen, donor type, GVHD, TRM and relapse rate. Correlation of TRM and relapse rate with the above-mentioned items were evaluated by univariate analysis using Fisher's exact test and logistic regression for independent variables. Table 3 Engraftment, GVHD and outcome 
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Results
All patients in our series engrafted successfully with a leukocyte count Ͼ1.0 g/l between days +10 and +25 (median +17). No graft failure or rejection has occurred. TRM was 36% (n = 4). Causes of death included cerebral haemorrhage on day +22 (n = 1), generalised CMV infection on day +61 (n = 1), sepsis with multiple organ failure on day +29 (n = 1) and late infection with respiratory failure on day +148 (n = 1). None of the patients grafted from a matched sibling donor died of transplant-related causes. Acute GVHD was observed in nine patients, including grade I in three patients, grade III in four patients (two after HLA-identical sibling transplants) and grade IV in two patients (donors were unrelated and 1AG mismatched mother, respectively). Organ involvement affected the skin (n = 3), skin and gut (n = 2) and skin, liver and gut (n = 4), respectively. Treatment consisted of prednisolone and cyclosporine in six patients, and three patients had additional IL-2 MoAB. Three patients developed extensive chronic GVHD.
Three of seven evaluable patients relapsed at 3, 6.7 and 7 months after BMT respectively, two after an HLA-identical sibling transplant. All patients with relapse had experienced acute GVHD, and one patient had extensive cGVHD at the time of relapse. Engraftment, GVHD, GVHD therapy and outcome are listed in Table 3 .
In Patient UPN 177, who received a sex-mismatched graft, chimerism was monitored by FISH and probes specific for the chromosomes X, Y and 7. This patient has been recently reported elsewhere. 12 Despite GVHD prophylaxis with cyclosporine and MTX she developed acute GVHD grade III and chronic GVHD, which were treated with prednisolone and cyclosporine. On day +200 she relapsed and 30% female cells with monosomy 7 could be detected in the bone marrow. Although reduction of prednisolone and withdrawal of cyclosporine led to remission, on day +360 extramedullary relapse with infiltrates in lymph nodes and skin occurred. Subsequently, BM cells of host origin increased in number. The patient died on day +693, in relapse from invasive aspergillosis.
Patient UPN 255 was treated with prednisolone and
Bone Marrow Transplantation cyclosporine for GVHD grade II, which resolved completely within 3 weeks. Chimerism was monitored by STR-PCR in whole bone marrow samples as well as in flow-sorted cell subsets.
On day +28 and +100 CD34 + cells showed mixed chimerism, the patient subsequently developed organomegaly, and on day +200 the majority of bone marrow cells were of recipient origin. Withdrawal of cyclosporine and donor lymphocyte infusion (DLI) with 1 × 10 7 /kg CD3 + cells were not successful. One year after BMT, a second transplant from the same donor without GVHD prophylaxis was performed. Conditioning consisted of TBI 12 Gy, additional splenic irradiation to 5 Gy and cyclophosphamide 120 mg/kg. The patient developed GVHD grade IV that required treatment with cyclosporine, prednisolone, IL-2 monoclonal antibody and ATG and was followed by extensive chronic GVHD (skin, sicca syndrome). She is still in complete remission with 100% donor cells on day +680 after the second BMT with a Lansky score of 80%.
Patient UPN 293 developed GVHD grade I which resolved after a short course of additional prednisolone until day +40. Chimerism was monitored by STR-PCR analysis of BM and PB cells. The patient developed fever and organomegaly 2 months after BMT, and PB CD34 + cells of recipient origin as well as monocytes with monosomy 7 could be detected in PB. Withdrawal of cyclosporine had no effect, and the patient underwent splenectomy and maintenance therapy with mercaptopurine, but CD34 + cells of recipient genotype were still detectable in PB. After DLI with 5 × 10 5 and 1 × 10 6 /kg CD3 + cells the cells of recipient genotype disappeared and mercaptopurine was discontinued. The boy is alive and in complete remission without GVHD on day +625 after BMT and 9 months after cessation of mercaptopurine therapy.
The probability of overall survival was 46%, and four patients, two of whom did not experience acute GVHD, are in continuous remission after a median observation time of 52.7 months (range 9.2-107.2).
Discussion
Allogeneic BMT is the only curative approach for JMML but is associated with a high TRM and a high relapse rate. As pretransplant therapy, donor selection, T cell depletion, conditioning regimens, and GVHD prophylaxis vary remarkably, there are still some open questions. We reviewed the literature for all single centre reports on allogeneic BMT in JMML patients since 1988 and attempted to summarise the different observations. [13] [14] [15] [16] [17] [18] [19] [20] [21] The published single centre experiences are listed in Table 4 . These detailed single centre reports together with our data reflect the experience in a total of 65 patients with JMML who underwent allogeneic BMT.
Overall relapse rate was 47% and 21% of the patients died of transplant-related causes. Our data and the different single centre reports confirm that BMT from alternative donors is associated with a significantly higher TRM. Twelve of 37 (32%) patients with alternative donors (mismatch family donor or matched unrelated donor) and 2/28 (7%) patients with sibling donors died of transplantrelated complications (P = 0.019).
Summarising the different single centre reports, we focused on the impact of pretransplant chemotherapy, conditioning regimen, GVHD and GVL effect on TRM and relapse rate and on the experiences concerning therapy after relapse. Data are summarised in Table 5 (TRM), Table 6 (relapse) and Table 7 (therapy after relapse).
Fourteen of 65 patients underwent BMT without any prior chemotherapy, 11 of them after an interval of less than 6 months between diagnosis and BMT. Twenty-two patients had received some kind of maintenance therapy mostly hydroxyurea, low-dose Ara-C or 6-mercaptopurine. Twenty-nine patients underwent high-dose chemotherapy protocols, containing Ara-C, etoposide and daunorubicin.
There was no significant difference in TRM between patients receiving no pretransplant chemotherapy (14%), those receiving maintenance therapy (27%) or intensive chemotherapy (20%). For patients treated exclusively with chemotherapy, high-dose chemotherapy is of no benefit in terms of relapse compared to nonintensive chemotherapy. 5 Lutz et al 22 postulate that intensive chemotherapy and splenectomy before BMT to reduce leukaemic burden might be beneficial. 22 However, chemotherapy does not seem to have an impact on relapse rate after BMT. 9 In the reviewed series pretransplant chemotherapy and splenectomy also had no significant impact on relapse rate after BMT.
The interval between diagnosis and BMT was reported in 60 patients, and patients who underwent BMT after an interval of more than 6 months seemed to have a higher risk of TRM although the difference is not significant (29% vs 14%, P = 0.152). This is consistent with the data published by Locatelli for the European Working Group on Myelodysplastic Syndrome in Childhood. Locatelli et al suggested that lower TRM after a shorter interval between 381 Number of patients (outcome), one patient underwent withdrawal of immunosuppression, donor lymphocyte infusion and 2nd BMT. TRM = transplant-related mortality.
diagnosis and BMT might be due to early BMT in patients with matched sibling donors. 9 However, in the single-centre experiences reviewed here an interval of less than 6 months between diagnosis and BMT did not correlate with the use of matched sibling donors. Taking into account that children with JMML are at risk of viral infections, and that causes of death were infections in all but one of the reported cases (three of them due to CMV), the higher TRM after delayed BMT might be due to disease-related immunosuppression and more infectious complications, especially CMV infection. Interval between diagnosis and BMT did not correlate with the incidence of relapse.
A total of 10 different conditioning regimens have been used. Thirty-eight patients received TBI-containing conditioning regimens and 27 received chemo-conditioning only.
TBI does not seem to have a significant impact on TRM. Relapse rate after the most frequently reported conditioning regimens was 6/18(33%) after busulfan/ cyclophosphamide/TBI, 7/13(53%) after cyclophosphamide/TBI and 2/10 (20%) after busulfan/cyclophosphamide/melphalan, which is currently being used in the EWOG-BMT cooperative study.
Urban et al 20 suggested that TBI might be the most effective myeloablative treatment for JMML. Locatelli et al 9 suggested that busulfan might have more antileukemic potential in JMML.
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Comparison of different conditioning regimens in our patient cohort and the other single-centre studies reported, revealed a significantly higher relapse rate in patients conditioned with TBI (61% vs 25%, P = 0.012). However, 53% of the patients conditioned with TBI plus busulfan relapsed.
GVHD prophylaxis was quite heterogeneous in the published patients: the regimen most frequently used consisted of cyclosporine, or cyclosporine + MTX, and a total of 16 patients were transplanted with T cell-depleted grafts. GVHD was diagnosed in 32/57 evaluable patients. GVHD Ͼ grade II was diagnosed in 12 patients, including five patients after HLA-identical sibling transplants and seven after transplants from alternative donors. None of the authors describe GVHD as the cause of death.
It is remarkable that no difference in relapse rate has been observed in patients with and without GVHD: 15/31 (58%) patients with GVHD vs 9/20 (45%) without GVHD (P = 0.64) relapsed.
In 11/24 relapsed children, a second curative attempt was reported. Patients with relapse, who underwent some kind of immunomodulating treatment or a second transplant, are summarised in Table 7 .
Reduction of immunosuppression led to remission in 2/5 patients, DLI led to remission in 1/2 patients, and seven children underwent a second transplant (one after DLI). Three of them were in remission at time of publication, two died from organ toxicity, and two from relapse after the second transplant.
Mouse models as well as in vitro human data indicate that the GVL effect might be separable from GVHD. 23, 24 The fact that relapse occurred despite GVHD and that remission could be induced by withdrawal of immunosuppression and/or DLI without GVHD suggests that in JMML also a GVL effect is not necessarily associated with GVHD. Moreover, it emphasises the importance of a GVL effect in JMML.
Median age of patients transplanted for JMML is 3 years and the incidence as well as severity of GVHD in this age group is not a major problem. 25 Reduced immunosuppression in patients transplanted for JMML might reduce the high relapse rate as well as the number of late infectious deaths. The fact that in 6/11 relapsed patients in the reviewed series achieved remission in response to immunomodulation and/or second BMT, should encourage making a second curative attempt in the event of relapse after BMT. Immunomodulation by modification of post-transplant immunosuppression, and adoptive therapy with donorderived lymphocytes might prevent and/or treat relapse after allogeneic BMT in these patients.
